Sep 2020 – EyRIS was awarded a 5-year contract for 
the deployment of SELENA+, an deep learning system to detect diabetic retinopathy, glaucoma and age-related macular degeneration in the Singapore Integrated Diabetic Retinopathy Program (SiDRP). This award is not only a milestone for EyRIS but also a world first in showcasing real world adoption of an artificial intelligence medical device in a national screening program.
SELENA+ attained its regulatory approval by the Singapore’s Health Science Authority (HSA) in Oct 2019, European CE Mark in March 2020 and Medical Device Authority of Malaysia in June 2020. This award-winning product was recently cited as one of five projects to be implemented under National AI Strategy unveiled by the Singapore government.
When SELENA+ goes live in November 2020, it will be initially deployed to screen 120,000 patients per year. The autonomous AI identifies images that require intervention which was traditionally performed by human graders. This will in turn make the screening process faster and more consistent, translating into reduction of workload and cost savings.
EyRIS’s SELENA+ is also deployed in 23 private optometric practices in Singapore on the “Say No To Vision Loss” platform.
About SELENA+
Early screening is highly effective in 
helping to prevent blindness from a range of eye diseases. SELENA+ is an intelligent deep learning system that can detect eye diseases: this system was jointly invented by researchers at NUS School of Computing (NUS-SoC) and the Singapore Eye Research Institute (SERI) to perform automated image analysis of retinal images. The analysis results will be used to provide early detection of eye diseases, including diabetic retinopathy (DR), glaucoma and age-related macular degeneration (AMD).
Comments are closed.